Mostrar el registro sencillo del ítem
Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | SCHNEIDER, Benjamin | |
hal.structure.identifier | Simulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc] | |
dc.contributor.author | BOYER, Arnaud | |
hal.structure.identifier | Simulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc] | |
dc.contributor.author | CICCOLINI, Joseph | |
hal.structure.identifier | Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM] | |
dc.contributor.author | BARLESI, Fabrice | |
hal.structure.identifier | Mayo Clinic [Rochester] | |
dc.contributor.author | WANG, Kenneth | |
hal.structure.identifier | Modélisation Mathématique pour l'Oncologie [MONC] | |
hal.structure.identifier | Institut de Mathématiques de Bordeaux [IMB] | |
dc.contributor.author | BENZEKRY, Sébastien | |
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | MOCHEL, Jonathan | |
dc.date.accessioned | 2024-04-04T03:01:18Z | |
dc.date.available | 2024-04-04T03:01:18Z | |
dc.date.issued | 2019-04-19 | |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/192889 | |
dc.description.abstractEn | Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) is a first line therapeutic for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BE V- PEM/CIS has a narrow therapeutic window. Therefore, it is an attractive target for administration schedule optimization. The present study leverages our previous work on BEV-PEM/CIS pharmacodynamic modeling in NSCLC-bearing mice to estimate the optimal gap in the scheduling of sequential BEV-PEM/CIS. We predicted the optimal gap in BEV-PEM/CIS dosing to be 2.0 days in mice and 1.2 days in humans. Our simulationssuggest that the efficacy loss in scheduling BEV-PEM/CIS at too great of a gap is much less than the efficacy loss in scheduling BEV-PEM/CIS at too short of a gap. | |
dc.language.iso | en | |
dc.publisher | American Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics | |
dc.subject.en | Cancers | |
dc.subject.en | Optimization | |
dc.subject.en | Oncology | |
dc.subject.en | Pharmacokinetics-pharmacodynamics | |
dc.subject.en | Mathematical modeling | |
dc.title.en | Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer | |
dc.type | Article de revue | |
dc.identifier.doi | 10.1002/psp4.12415 | |
dc.subject.hal | Informatique [cs]/Modélisation et simulation | |
dc.subject.hal | Sciences du Vivant [q-bio]/Cancer | |
dc.subject.hal | Physique [physics]/Physique [physics]/Analyse de données, Statistiques et Probabilités [physics.data-an] | |
dc.subject.hal | Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie | |
dc.subject.hal | Statistiques [stat]/Applications [stat.AP] | |
bordeaux.journal | CPT: Pharmacometrics and Systems Pharmacology | |
bordeaux.hal.laboratories | Institut de Mathématiques de Bordeaux (IMB) - UMR 5251 | * |
bordeaux.institution | Université de Bordeaux | |
bordeaux.institution | Bordeaux INP | |
bordeaux.institution | CNRS | |
bordeaux.peerReviewed | oui | |
hal.identifier | hal-02109335 | |
hal.version | 1 | |
hal.popular | non | |
hal.audience | Internationale | |
hal.origin.link | https://hal.archives-ouvertes.fr//hal-02109335v1 | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=CPT:%20Pharmacometrics%20and%20Systems%20Pharmacology&rft.date=2019-04-19&rft.au=SCHNEIDER,%20Benjamin&BOYER,%20Arnaud&CICCOLINI,%20Joseph&BARLESI,%20Fabrice&WANG,%20Kenneth&rft.genre=article |
Archivos en el ítem
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este ítem. |